Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endo...

Full description

Saved in:
Bibliographic Details
Main Authors: Merz, Patrick (Author) , Ballikaya, Seda (Author) , Auffarth, Gerd U. (Author) , Schmack, Ingo (Author)
Format: Article (Journal)
Language:English
Published: 11 December 2018
In: BMC ophthalmology
Year: 2018, Volume: 18
ISSN:1471-2415
DOI:10.1186/s12886-018-0978-9
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12886-018-0978-9
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12886-018-0978-9
Get full text
Author Notes:Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack
Description
Summary:Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium.
Item Description:Gesehen am 21.12.2018
Physical Description:Online Resource
ISSN:1471-2415
DOI:10.1186/s12886-018-0978-9